

Cerebrolysin in Steel: Richardson-Olszewski Syndrome

A Mubaidin, A Shurbaji, A Hadid, N Shishani

Citation

A Mubaidin, A Shurbaji, A Hadid, N Shishani. *Cerebrolysin in Steel: Richardson-Olszewski Syndrome*. The Internet Journal of Neurology. 2002 Volume 2 Number 1.

Abstract

Objectives: The authors investigated the effectiveness of Cerebrolysin, a neurotrophic factor, in 6 patients with Steel-Richardson-Olszewski (Progressive supranuclear palsy) also known by Ophthalmo-facial-cervical dystonia. **Methods:** 6 patients (mean age 67.8 years) with progressive supranuclear palsy (PSP), mean duration of disease 3.8 years, were treated with Cerebrolysin 10 ml intravenous infusion on a daily basis for 20 days to be repeated every 2 months for a total of 6 months. Progressive supranuclear palsy rating scale and staging system (PSPRS) were assessed at baseline and after 6 months. **Results:** Five patients continued the study period; 5 patients showed modest improvement on (PSPRS) score. Side effect of Cerebrolysin was negligible. **Conclusion:** This study showed that Cerebrolysin has modest effect in the treatment and delaying progression in patients with PSP.

INTRODUCTION

Progressive Supranuclear Palsy (PSP) described by Steel – Richardson- Olszewski syndrome in 1964 (SROS) is a neurodegenerative disorder of unknown etiology. Pharmacological therapy has been disappointing^{1,2}.

PSP usually presents itself in the seventh decade with early postural instability, vertical supranuclear gaze palsy (affecting chiefly vertical gaze), pseudobulbar palsy, dysarthria, dystonic rigidity of the neck and upper trunk, frontal subcortical dementia, and parkinsonism. Clinical symptoms started between 48 and 51 years of age with slow progression during 2 to 4 years. Many of the symptoms present in PSP do not respond to dopamine stimulation. The potential benefits of these compounds are restricted to akinesia and rigidity³. Also the effectiveness of dopamine agonist is similar³.

Cerebrolysin is a peptidergic solution containing free amino acids and biologically active peptides with proven neuroprotective and neurotrophic effect⁴. This drug has previously been used in the treatment of brain dementia⁴, Parkinson disease⁵, and stroke⁶.

METHODS

Six patients with PSP entered the open label study. Patients were recruited for the study during their routine outpatient visit to King Hussein Medical Center. All patients fulfilled the National Institute of Neurological Disorders and Stroke

(NINDS) clinical criteria for the diagnosis of PSP. No levodopa or any dopamine agonist was allowed during the study period. Cerebrolysin was given 10 ml intravenous infusion on a daily basis for 20 days to be repeated every 2 months for a total of 6 months. Progressive supranuclear palsy rating scale and staging system were assessed at baseline and after 6 months. The Ethical committee of the King Hussein Medical Center approved this study.

RESULTS

One of the six patients died 2 months after starting treatment due to myocardial infarction. Five patients (mean age 67.8 years, mean duration of disease 3.8 years) continued on Cerebrolysin for 6 months. There was modest improvement in the Progressive supranuclear palsy rating scale and staging system as seen in table 1. There was slowing in progression in our treated group according to (PSPRS) score in 2 patients. The remaining 3 patients had slight worsening in their PSPRS from baseline, but we still consider their condition as improved, since their PSPRS were lower than their expected PSPRS at 6 months. Side effects of Cerebrolysin was negligible.

Figure 1

Patient	Age	Disease duration	Baseline PSPRS	PSPRS at 6 months	Baseline PSP staging	PSP staging system at 6 months	Expected PSPRS at 6 months
Number 1	69	4.1	64	62	3	3	70
Number 2	63	2.9	51	50	2	2	57
Number 3	72	3.7	58	-	3	-	64
Number 4	67	4.3	72	75	1	1	78
Number 5	69	3.5	61	62	2	1	67
Number 6	71	4.4	69	62	4	4	75

DISCUSSION

Cerebrolysin has been used in parkinson's disease where improvement of symptoms was observed⁵, and was also found effective-among others conditions- in dementia and stroke^{6,7}. It has also been shown to be effective in the treatment of Alzheimer's disease in earlier trials.

Cerebrolysin (Cere) is a compound with neurotrophic activity that cause neuronal differentiation (sprouting of axons and dendrites,) and maintains the functional integrity of the nerve cell⁴.

The (PSPRS) has a range of scores from 0 (normal) to 100. The PSPRS includes questions on activities of daily living ascertained historically and examination items on behavior, bulbar function, eye and eyelid movement, limb movement and midline movement/gait. The mean rate of progression from the time of symptom onset to the first administration of the PSPRS was .98 point per month for men and .85 points per month for women⁸.

As with all parkinsonian disorders, levodopa is always tried in order to ameliorate the symptoms of rigidity and bradykinesia, but as with the other non-PD neurodegenerative parkinsonisms, response is generally poor^{3,9,10}.

Dopamine receptor agonists are likewise unhelpful¹¹ and trials of pramipexole (Mirapex) have not borne out success¹². Despite the severe cholinergic deficit in PSP, cholinergic drugs have been used without benefit^{13,14,15}.

Zolpidem (Ambien) has been reported to help parkinsonism and eye movements but the benefit was brief¹⁶.

Tricyclics have modest beneficial effect, mainly Amitriptyline, on gait disorder and eyelid apraxia³. Despite the severe cholinergic deficit in PSP, cholinergic drugs have been used without significant benefit¹³. Amantadine, which has also anticholinergics effects, was found to have modest benefit in PSP³. Electroconvulsive therapy (ECT) was of limited value in PSP¹⁷. A new compound being tested in Japan, tadospirone citrate, a partial serotonin (5-HT 1A)

receptor agonist, has recently been reported to be effective^{18,19}.

In this open label trial patients did demonstrate modest efficacy of cerebrolysin, and in delaying progression in patients with PSP. The true mechanism by which this drug work in such a degenerative disease is still unknown, but probably the neuronal differentiation (sprouting of axons and dendrites) and the maintenance of the functional integrity of the nerve cell play a major role in the improvement encountered in this trial.

The side effect of cerebrolysin was negligible, so the absence of adverse effect in cerebrolysin treated patients confirms an extreme wide margin of safety for this drug, however longterm efficacy and safety of Cerebrolysin in SROS' patients should be evaluated in the future. A protective investigation using this compound on a biggest number of patients with similar presentation of SROS should be done in a randomized, double-blind, placebo controlled trial.

CORRESPONDENCE TO

Mubaidin A Department of Neurology King Hussein Medical Center Amman- Jordan. P.O.Box: 926442 Amman 11110 E-mail: drammar@go.com.jo

References

1. Kompoliti K, Goetz CG, Litvan I, Jellinger K, Verny M. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998 Aug; 55(8): 1099-102.
2. Rascol O, Sieradzan K, Peyro-Saint -Paul H, Thalamas C, Brefel-Courbon C, Senard JM, Ladure P, Motastruc JL, Lees A. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Mov Disord 1998 Jul; 13(4): 673-6.
3. Nieforth KA, Globe LI, Retrospective study of drug response in 87 patients with PSP. Clin Neuropharmacol 1993; 16:338-346
4. Satou T et al.: Morphological observation of effect of cerebrolysin on culture neural cells. Advances in Biosciences, 1993; 87:195-196,
5. Balenty A et al. Erste Ergebnisse Der Anwendung von cerebrolysin an patienten mit morbus Parkinson. Neuropsychiatrie 1987; 1:94-7
6. Klein K. Erfahrungen mit einer rheologisch und metabolisch aktiven wirkstoffkombination bei akuten zerebralen ischamien. Therapiewoche 1985; 35:2323-30
7. Rainer m et al. therapeutic results with cerebrolysin in the treatment of dementia. Wien med Wschr 1997; 147:426-31
8. Golbe LI and the medical advisory board of the society for PSP.A clinical rating scale and staging system for PSP. Neurology 48(suppl): A326, 1997
9. Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 1983; 13:273-278.
10. Kompoliti K, Goetz CG, Litvan I, et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol

1998; 55:1099-1102.

11. Neophytides A, Lieberman AN, Goldstein M, et al. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry* 1982; 45:261-263.

12. Wiener WJ, Minagar A, Shulman LM. Pramipexole in progressive supranuclear palsy. *Neurology* 1999; 52:873-874.

13. Litvan I, Gomez C, attack JR, et al. Physostigmine in progressive supranuclear palsy. *Ann Neurol* 1989; 26:404-407

14. Litvan I, Blesa R, Clark K, et al. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. *Ann Neurol* 1994; 36:55-61.

15. Frattali CM, Sonies BC, Chi-Fishman G, Litvan I. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study. *Dysphagia* 1999; 14:165-168.

16. Daniele A, Moro E, Bentivoglio AR. Zolpidem in

progressive supranuclear palsy. *N Engl J Med* 1999; 341:543-544.

17. Barclay CL, Duff J, Sandor P, Lang AE. Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy. *Neurology* 1996; 46:1284-1286.

18. Watanabe H, Arahata Y, Tadokoro M, Kato T, Sobue G. Effects of tandospirone citrate on frozen gait in patients with early stage of progressive supranuclear palsy, investigated by walk-induced activation single photon emission computed tomography method. *Rinsho Shinkeigaku (Clin Neurol)* 2000; 40:1130-1132.

19. Iijima M, Terashi H, Iwata M. A case of progressive supranuclear palsy improved with tandospirone citrate. *Rinsho Shinkeigaku (Clin Neurol)* 2001; 41:150-153.

20. PanisetM, Gautier S, Moesser H, Windisch M; The Cerebrolysin Study Group Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo controlled trial with a neurotropic agent. *J Neural Transm* 2002 Jul;109(7-8):1089-104

Author Information

A. Mubaidin

Department of Neurology, Department of Pharmacy, King Hussein Medical Center,

A. Shurbaji

Department of Neurology, Department of Pharmacy, King Hussein Medical Center,

A. Hadid

Department of Neurology, Department of Pharmacy, King Hussein Medical Center,

N. Shishani

Department of Neurology, Department of Pharmacy, King Hussein Medical Center,